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Abstract
Background: Receiving real-time information on tissue properties while performing biopsy procedures has the
potential of improving biopsy accuracy. The study goal was to test the ability of a miniature flexible Radio-Frequency
(RF) sensor (Dune Medical Devices), designed to be mounted on the surface of surgical tools, in measuring and
mapping the various breast tissue types and abnormalities in terms of electrical properties.
Methods: Between January and October 2012, 102 patients undergoing lumpectomy, open-biopsy or mastectomy, in
3 medical centers, were enrolled in this study. The device was applied to freshly excised specimens, with registration
between device measurements and histology analysis. Based on histology, the dielectric properties of the various tissue
types were derived. Additionally, the ability of the device to differentiate between malignant and non-malignant tissue
was assessed.
Results: A total of 4322 measurements from 106 specimens from 102 patients were analyzed. The dielectric properties
of 10 tissue types in the low RF-frequency range were measured, showing distinct differences between the various
types. Based on the dielectric properties, a score variable was derived, which showed a correlation of 90 % between
the RF measurements and the tissue types. Differentiation ability between tissue types was characterized using ROC
curve analysis, with AUC of 0.96, and sensitivity and specificity of 90 and 91 % respectively, for tissue feature sizes at or
above 0.8 mm.
Conclusions: Using a radio-frequency near-field spectroscopy miniature flexible sensor the dielectric properties of
multiple breast tissue types, both normal and abnormal, were evaluated. The results show promise in differentiating
between various breast tissue types, and specifically for differentiation between cancer and normal tissues.
Keywords: Breast cancer, Lumpectomy, Breast biopsy, Surgical margin, Radio-frequency near-field spectroscopy
Background
The response of matter to electromagnetic fields is char-
acterized by the material’s dielectric properties: permit-
tivity and conductivity. The conductivity is a measure of
the ease with which free electric charges can migrate
through the material; the permittivity reflects the extent
to which bound charge distributions can be distorted
through polarization by an external field.
Differences in dielectric properties between human
tissues and specifically between benign and malignant
tissue have been studied and are well established [1–3].
Tissue dielectric properties are determined by concen-
tration and mobility of intra and extracellular compo-
nents, cell size, structure and arrangement, amongst
other characteristics. Specifically, the tissue dielectric
properties have been extensively studied in breast tissue
[4–7], where differences between tissue types, and spe-
cifically between normal and malignant were observed
over a broad range of frequencies. These properties have
been successfully used to differentiate between normal
and malignant breast tissue [8, 9] and for intraoperative
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margin assessment during lumpectomies [10]. Normal
breast tissue is heterogeneous, being composed of three
different types of tissue (Adipose, Glandular, and
Connective), In all the studies to date, the evaluated
dielectric properties were based on measurements and
comparisons performed on scales larger than the intrin-
sic scale of tissue heterogeneity within breast tissue.
Therefore, the differences observed represent average
values of the dielectric properties. Results were generally
reported on properties of “normal” and “cancer” types.
In some reports [5, 7] an attempt has been made to
partition between the three intrinsic tissue types of the
normal breast. There has been no reporting on the
specific properties of glandular and connective tissue
types. Also, cancer of the breast has three major types:
Ductal Carcinoma in Situ (DCIS), Invasive Ductal
Cancer (IDC), and Invasive Lobular Cancer (ILC). The
dielectric properties of these types, to date, have not
been characterized separately. Additionally, specifically
of importance in breast biopsy procedures, the dielectric
characteristics of abnormalities in the breast that may
progress to cancer, such as: non-malignant proliferative,
non-malignant proliferative with atypia, and LCIS, have
not yet been characterized.
The burden of breast cancer is high. Approximately
230,480 American women are diagnosed annually, and
39,520 women die from this disease [11]. Global cancer
statistics show that breast cancer is the most frequently
diagnosed cancer and the leading cause of cancer death
among females, accounting for 23 % of total cancer cases
and 14 % of cancer deaths [12]. The majority of breast
cancers are diagnosed as a result of an abnormal
mammogram or ultrasound, and in selected populations
abnormal MRI findings. Some lesions are found by the
patient or her physician as a palpable mass. Not all
abnormal findings diagnosed by the methods mentioned
represent cancer. To determine whether a mass in the
breast is a suspicious mass or not the BI-RADS System
was developed [13]. All patients with a BI-RADS
category of 4 and 5 should undergo a biopsy. Those with
category 3 should be followed more frequently. A clinic-
ally suspicious mass should also be biopsied, regardless
of imaging findings, as about 15 % of such lesions can
be mammographically occult [14].
Screening mammography is the most common way to
diagnose early breast cancer but carries a high rate of
recalls (16.3 % at first and 9.3 % at subsequent
mammography) [15]. Biopsy is further recommended in
0.6–1 % of all screened women [16, 17]. Millions of
women are screened each year, therefore these figures
represent a high number of breast biopsies performed
each year, emphasizing the need for accurate biopsy.
During the breast biopsy procedure part or all of a
suspicious breast tissue growth is sampled and examined
for the presence of cancer, most often in a minimally
invasive procedure. Current biopsy techniques have
several limitations: First, patients diagnosed with
Atypical Ductal Hyperplasia (ADH) are routinely sent
for an open surgical biopsy, following which 10–25 % of
these patients’ diagnosis will be ‘upgraded’ DCIS, which
requires a further lumpectomy or mastectomy [18–21].
Second, patients with a diagnosis of DCIS in biopsy will
undergo lumpectomy, typically without a sentinel lymph
node biopsy. Following the Lumpectomy, about 20 % of
these patients’ diagnosis will be upgraded to invasive
cancer, requiring a further surgery for node biopsy.
Third, studies have shown that up to 10 % of patients
endure repeat biopsies [22, 23]. These repeat biopsies
reveal carcinoma in up to 25 % of cases [24]. Forth,
published data show a 1–7 % false negative rate with
current breast core biopsy techniques [25].
The inaccuracies in the biopsy procedure result mainly
from the uncertainty in the exact location from which
the biopsy sample is taken relative to the image, and
from the fact that the features presented on imaging
may not be the most abnormal tissue present. Having an
in-situ, at the needle tip, tissue characterization ability
when performing biopsy procedures has the potential to
increase the accuracy of the procedure.
In the presented study, we use a miniature, 0.8 mm in
diameter, RF sensor to characterize the dielectric proper-
ties of different breast tissue types and abnormities.
Based on these characteristics, we tested the potential of
this type of sensor in differentiating between normal,
abnormal, and malignant breast tissue. The sensor has a
coaxial opening that results in a fringing electrical field
close to the sensor surface. The sensor is manufactured
using flexible printed circuit board technology and can
be potentially placed on various devices having different
geometries, such as open surgical tools as well as
minimally invasive ones, like core biopsy needles. A
similar device has been already been used for evaluating
freshly excised radical prostatectomy specimens [26].
Material and methods
Ethics, consent and permissions
The study was performed at 3 sites under institutional
review board approval and in accordance with the
Declaration of Helsinki. All subjects signed an informed
consent.
General design
Between January to October 2012, subjects undergoing
lumpectomy, open biopsy or mastectomy procedure
were enrolled. Inclusion criteria specified subjects over
18 years of age.
Tissue measurements were performed on freshly
excised breast specimens. Measurements were compared
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to histological analysis. All medical staff members were
blinded to device output. Specimen handling before and
after measurements was performed according to routine
procedures. As the device was used on ex-vivo speci-
mens in the pathology lab, safety aspects (adverse
effects) of the study and device use were monitored only
with regards to specimen handling and analysis.
Device description
The device (Dune Medical Devices Ltd., Israel) used in this
study is a near-field Radio-Frequency (RF) spectroscopy-
based real-time detection device. It consists of a hand-held,
pencil like, probe, connected by cables to a console. The
console sends RF waves at several frequencies, transmitted
to the tissue through the sensor at the probe’s tip. The
frequencies (4–30 MHz) were chosen based on design
considerations, and on where differences between breast
tissue types are expected to be substantial [5, 6]. The
frequency range at which the tissue is probed has no
ionizing effects. The amplitude of the transmitted RF field
across the sensor opening is low. The voltage across the
sensor is ~ 0.1 Volts, much lower than the ionization
voltage. The transmitted RF power is ~ 0.1 mW per square
mm. Each measurement takes ~ 3 msec. The RF signals are
reflected from the tissue through the sensor, and are
received by the console. The sensor is designed as a multi-
layer transmission line structure with a coaxial end
opening. It is fabricated from flexible circuit board
materials, making the sensor (including the transmission
line structure) mechanically flexible and thin. The sensor
coaxial end conductive regions are gold–plated. The
diameter of the sensor coaxial end is 0.8 mm. The sensor
end is attached to the flat tip of the probe. The size of the
coaxial sensor is much smaller than the transmitted wave-
lengths, as the highest frequency of 30Mhz corresponds to
a wavelength of 10 m. Under this condition the penetration
depth of the field is ~0.078 of the coaxial opening [27]. This
translates to a penetration depth of ~0.07 mm.
The sensor has a coaxial opening that results in a frin-
ging electrical field close to the sensors surface, which
enables direct calculation of the impedance (dielectric
properties - permittivity and conductivity) of the tissue
in contact with the sensor. Signals at specific frequencies
are transmitted to the sensor. The fringing field interacts
with the tissue so that the reflected signals are
dependent on the impedance of the tissue close to the
sensor. From the reflection amplitude and phase the
impedance of the tissue at each frequency measured is
extracted using the process described in [28].
Tissue measurements and processing
Following excision, the fresh specimens were directly
delivered to the pathology laboratory; the fresh, non-
fixed, specimens were then fully inked and sliced into
5–7 transverse sections, approximately 1 cm thick, in
a bread-loaf manner.
One or two transverse-cut sections were immediately
sampled by the probe. The time between performing the
measurements and tissue excision was no longer than
30 min. Specially designed stencils were placed on the
slice. These stencils contained a matrix of holes of diam-
eter 3.2 mm, which accommodated the probe’s distal
end, enabling it to contact the tissue surface (Fig. 1).
The grid spacing was 6 mm. The probe was operated
manually to measure all measurement sites of the slice
through the stencil (Fig. 1). Good contact between the
sensor and tissue was achieved by applying mechanical
pressure by hand to the tissue in the stencil holes. Each
individual measurement took 1–3 s to complete.
Designated software utility helped the user to record the
location of the measurements within the stencil. Once a
slice was fully measured it was fixed (24–48 h) and
further processed for histological analysis. The histo-
logical analysis of the slices was performed en-face,
without any further sectioning, so that the full surface of
the measurement locations was available for histological
examination. The relative position of the stencil and the
slice was maintained, thus the sampling locations remain
fully registered. The Histological slides were prepared
for each measured slice. As the diameter of the stencil
holes is 3.2 mm and the probe tip diameter is 3.0 mm, it
is estimated that the potential registration error between
the actual measured site and the analyzed tissue sample
was less than 0.1 mm.
Data analysis
Tissue
Each measurement site was histologically analyzed. The
tissue composition and feature sizes of the various tissue
types present were recorded. The sites were then classi-
fied according to their most advanced abnormality
within the 1 mm central area and divided into 6
Fig. 1 Measurement method of the tissue slices with and apparatus
and stencil probe. Inset: histology slide of four measurement sites
with their respective stencil coordinates
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categories [29]: 1) normal and non-malignant non-
proliferative abnormal tissue; 2) non-malignant proliferative
abnormal tissue; 3) non-malignant proliferative tissue with
atypia; 4) LCIS; 5) DCIS and 6) invasive cancer.
Measurements
The permittivity and conductivity of each measured
tissue site were extracted at all measured frequencies.
Dielectric properties
A subset of measurements in which the size of a given
tissue type, the feature size, was larger than 0.7 mm was
used for assessment of dielectric properties of various
tissue types. As the sensor’s size is 0.8 mm, selection of
such feature sizes ensures that the sensor came in
contact with the specific tissue type being assessed.
Analysis was performed by linear regression [30]. Only
tissue types presenting in >5 samples were considered.
This provided an estimation error of no more than 50 %.
Score variable
The same subset of measurements used to determine
the dielectric properties of tissues was used in order to
derive a single score variable. The score variable was cal-
culated as a linear combination (using linear discrimin-
ant analysis) [31] of the dielectric properties, a linear
combination that exhibited differentiation between two
selected categories, e.g. normal and malignant tissue.
The discriminant analysis was performed for each meas-
urement frequency separately. The analysis presented is
based on the results for 10 Mhz. The correlation of the
score variable values with tissue type categories was
characterized by a linear regression analysis.
ROC curve analysis
A dichotomous device output (positive/negative) for
each measurement was derived by placing a threshold
for the score variable value. Measurements with a score
value lower than the threshold were defined as being
negative, and those above the threshold were defined as
being positive. Device indication (positive/negative) of
qualified measurements was compared to tissue
histology. The threshold levels of the score variable were
scanned to generate receiver operating characteristics
(ROC) curves. Sensitivity and specificity at the optimal
cutoff points (points on the ROC curve closest to the
upper left corner of the axes) were extracted. This
analysis was repeated for normal vs. all abnormal types
(malignant and non-malignant). The score variable of
normal vs. malignant tissues was also used to estimate
the differentiation ability as a function of the malignant
tissue feature size.
Results
Out of 104 enrolled subjects, 102 were analyzed (their
baseline characteristics are presented in Table 1). Two
subjects were excluded from the analysis: one due to
neo-adjuvant treatment and one specimen was inserted
into formaldehyde prior to device use. Four subjects had
bilateral surgery, thus 106 specimens were included in
the analysis. Device measurements were found to be
non-destructive and had no effect on the specimens or
on the ability to inspect them histopathologically.
In the 106 specimens included in the analysis 5262
measurements were performed. Altogether 940 measure-
ments (18 %) were not analyzed. 388 sites were not
reproduced during slide preparation, i.e. no histology to
compare to measurement, and in 119 sites the exact
registration between measurement site and histology
could not be verified. The remaining 433 sites were
disqualified due to predefined criteria related to poor
quality of the histology slides (fragmented tissue, torn
tissue, uneven tissue surface, color covering sample).
Altogether, 4322 measurements were analyzed. The
distribution of tissue histology of all qualified tissue
measurements is shown in Table 2. Note that the
Table 1 Patient Cohort
Characteristic Value
Number of Patients 102
Number of Specimens 106




















a5 ADH, 10 Fibroadenoma, 4 Other
b9 Undetermined
c24 Undetermined
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numbers present the most advanced abnormality, ac-
cording to the established 6 category scale described
earlier, within each tissue site analyzed. This was re-
corded irrespective of size of the abnormality within the
sensed area. For example, in some of the sites catego-
rized as malignant some non-malignant abnormalities
may be present, as well.
Dielectric properties
The dielectric properties (conductivity, y-axis, and
permittivity, x-axis) of 10 tissue types, as assessed from
the data at 4, 10 and 30 MHz, are presented in Fig. 2.
The assessment was based on a subset of 1253 tissue
measurements which had feature sizes above 0.7 mm of
a single tissue type. The dielectric properties were calcu-
lated using a linear regression with respect to the
relative tissue compositions of these samples. Only tissue
types that were present within at least 5 samples were
analyzed. The estimation error for each tissue type is
also presented. The error depends on the actual spread
of values as measured, the feature sizes, and the number
of the samples at which a given tissue type is present
(e.g. the error for ADH is larger as the number of
samples containing ADH was only 7). Additional tissue
types present in the breast were either not present in the
subset or were very rare, rendering the assessment
impractical. The results are similar across the frequency
range measured, but the distinction between the various
breast tissue types is clearer at 4 and 10 MHz.
Correlation between tissue types and score variable
Figure 3 presents the average (and standard deviation) of
the score variable (y-axis), derived based on the tissue
dielectric properties, vs. the tissue type categories (x-axis).
Although tissue were grouped into 6 categories, in the
data used (feature size >0.7 mm) for this analysis only 4
categories were present (after excluding Fibroadenoma).
LCIS and proliferative lesions were not present in these
samples. The more severe the tissue abnormality, progres-
sing from left to right, the higher the score variable,
starting at -0.4 (+/- 1.2) for normal and non-proliferative
abnormal tissue, up to 2.6 (+/- 1.4) for invasive cancer.
The linear regression coefficient between the score
variable and the tissue type grouping for the dataset was
0.59 [95 % CI: 0.11–1.07, P = 0.033]. The need to identify
an abnormality such as Fibroadenoma is usually in young
women, where these are the majority of the biopsy
findings. In these young women the prevalence of cancer
(or atypia) is very low. In women who are biopsied with
more “suspicion” for cancer, the more relevant differenti-
ation required does not include Fibroademona. Therefore,
Fibroademona presents an “isolated” tissue type, with the
background tissue being, most always, normal breast
tissue.
Differentiation between tissue categories
It is clear from Fig. 2 that various tissue types have
different dielectric properties. To further assess whether
these differences can serve as a basis for differentiation
between various tissue categories, the subset of measure-
ments with feature sizes of >0.7 mm was grouped into
binary categories. The resulting ROC curves for two
interesting cases, normal vs. malignant (blue line) and
normal vs. all abnormal types (red line), are presented in
Fig. 4. In both cases the curves follow the left and upper
axes, reaching very close to the upper left corner, with
the areas under the curve approaching unity; 0.95 (95 %
CI: 0.94–0.96) and 0.96 (95 % CI: 0.94–0.97), respect-
ively. The sensitivity and specificity evaluated for each
curve at the optimal cut-off point (the point in the curve
closest to the upper left corner) are: Sensitivity 90.5 %
(95 % CI: 86–94) and Specificity 90.1 (95 % CI: 88–92)
for differentiating between normal and malignant tissue,
and Sensitivity 88.6 % (95 % CI: 85–92) and Specificity
91.7 (95 % CI: 90–93) for differentiating between normal
and all abnormal tissue types, both malignant and non-
malignant.
In general, it is expected during a biopsy procedure to
encounter lesions of ~1 mm or larger. From analysis of
SEER (Surveillance, Epidemiology, and End Results
program of the National Cancer Institute) data, more
than 97 % of the malignant lesions are larger than 3 mm
[32]. Still, it is interesting to analyze the separation abil-
ity of the device between normal and malignant tissues
for various tissue feature sizes. Figure 5 presents 3 ROC
curves for 3 feature size categories - above 0.8 mm (the
size of the sensor), 0.5–0.8 mm and below 0.5 mm
(including any detectable cancer by pathology, even
below 0.1 mm). As seen in the figure, the ability to
detect cancer (quantified by the areas under the curves,
also presented in Table 3) depends, as expected, on the
Table 2 Distribution of tissue histology
Tissue type Number of samples
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Fig. 2 Dielectric properties, evaluated from measurements performed at 4, 10 and 30 MHz (top to bottom), of various tissue types
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feature size. Table 3 also presents the sensitivity and
specificity for each case at the optimal cutoff point of
the score variable.
Discussion
Our results quantify dielectric properties of 10 different
tissue types present within the breast, and show that
they all have different dielectric properties. These
includes the types related to normal breast tissue
(Adipose, Glandular, and Connective), and types associ-
ated with various abnormalities, including the differenti-
ation between the dielectric properties of the 3 types of
cancer types: IDC, ILC, and DCIS. Prior studies [4–7]
have demonstrated that, generally, there are differences
between normal and cancer tissue within the breast, but
have not provided the level of differentiation presented
in this work. Additionally, the data on the dielectric
properties of pre-malignant types is new. These identi-
fied differences served as a basis for constructing a score
variable that demonstrated correlation with the degree
of abnormality, including pre-malignant phase, of the
breast tissue. Additionally, using the dielectric properties
and the score variable good differentiation between
normal and malignant, or non-malignant abnormal,
tissue was established. The configuration of the sensor
as a 0.8 mm circular sensor can be thought of as a basic
sensing unit for use in breast biopsy procedures, with an
array of sensors aligned along the biopsy needle.
The goal of the initial biopsy is to obtain sufficient
diagnostic material using the least invasive approach and
to avoid surgical excision of benign lesions. CNB offers a
definitive histologic diagnosis, avoids inadequate samples
Fig. 3 Correlation of score variable (blue diamond denotes the
average value and the bars the standard deviation) and tissue type
divided into 6 categories
Fig. 4 ROC curve analysis of normal vs. malignant measurement
sites (blue) and normal vs. abnormal measurement sites (red) in the
subset with feature sizes of >0.7 mm
Fig. 5 ROC curve analysis of normal vs. malignant measurement
sites as function of cancer feature size, for full dataset
Table 3 Differentiation ability for various cancer feature sizes
Feature size Sensitivity Specificity AUG
>0.8 mm 90.2
(95 % CI: 84–95)
90.9
(95 % CI: 90–92)
0.957
(95 % CI: 0.95–0.96)
0.5 to 0.8 mm 73.1
(95 % CI: 66–80)
80.4
(95 % CI: 79–82)
0.84
(95 % CI: 0.83–0.85)
<0.5 mm 66.8
(95 % CI: 60–74)
72.8
(95 % CI: 71–74)
0.75
(95 % CI: 0.74–0.77)
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and may permit the distinction between invasive versus
in situ cancer. In most centers, image guided CNB has
replaced wire localization and surgical excision as the
most common initial biopsy method for nonpalpable
abnormalities [33–35]. The accuracy of CNB was shown
in a series of 952 consecutive breast CNBs performed at
one institution (342 without image guidance, 241 with
ultrasound guidance, and 369 using a stereotactic
vacuum assisted biopsy (VAB)) [36]. The false-negative
rate with 11-gauge VAB was 3 %, compared to 13, 5, and
22 % for non-image guided, surgeon-performed
ultrasound-guided, and 14-gauge VAB, respectively. In
most of these false negative patients (5–22 %) the reason
for the false negative result was due to sampling error,
meaning that the biopsy was not taken from the lesion
as planned.
The false negative rate can be reduced by using very
large needles [37]. An alternative approach could be to
keep the needle size relatively small, but add local
sensors located at the needle’s tissue collection region
that provide in-situ information on the tissue about to
be sampled. The basic units for these sensors can be
sub-millimeter, circular near-field radio-frequency
sensing units, as those we have used in this work for
characterizing breast tissue properties. These sensors
may provide real-time measurements of tissue dielectric
properties at the locations of tissue to be biopsied. As
the power transmitted by the sensor is very low and the
RF radiation is non-ionizing, these type of sensors are
well suited for in-vivo use.
As per the current standard of care, imaging will be
used to direct the needle to the general location of the
suspected abnormality. The in-site sensors will provide
indication of the tissue type at the immediate vicinity of
the needle and in contact with the sensor, as the sensor
is effectively a surface characterization sensor. The
penetration depth the 0.8 mm sensor in no more than
0.1 mm. By scanning/moving the needle around the
suspected region, the most suspicious tissue abnormality
can be identified, and biopsied. The spatial resolution of
a sensing device designed using the sensors as the basic
building blocks is dictated by the sensor size and by the
ability to arrange sensors close together. Arranging
0.8 mm sensors in an array will preserve this resolution,
as the sensors can share the same ground plane (the
outer conductor of the coaxial aperture).
For a potential set-up for use in a biopsy device
configuration, approximately 10 0.8 mm circular sensors
will be arranged in a 1D array on the biopsy needle, in a
location overlapping the biopsy sampling cavity. As each
measurement takes approximately 2.5 msec, a reading
from all 10 sensors will take ~ 0.025 s. The full measure-
ment cycle, including displaying the results to the user,
will take approximately 0.2 s, thus providing real-time
tissue characterization as the needle is progressed
through the tissue. Therefore, when the sensors will be
integrated with the biopsy needle, it is anticipated that
the duration of the biopsy procedure will not be
extended.
DCIS is presented mostly as microcalcifications on
mammography and diagnosed by stereotactic mammog-
raphy guided biopsy (mammotomy). The ability of the
sensor to distinguish between DCIS and normal breast
tissue elements seems promising for using this type of
sensor also in mammotomies.
Patients with ADH that were diagnosed on a CNB will
be found to have in up to 25 % DCIS or even IDC present
at open biopsy. Therefore patients with ADH on CNB are
routinely sent for an open surgical biopsy [18–21]. A more
accurate CNB can reduce the number of unnecessary
open biopsies in these patients. The ability of the sensor
to differentiate between normal breast tissue, ADH and
DCIS, can potentially improve the accuracy of CNB and
reduce the number of open biopsies.
The diagnostic capability of the sensor for differentiat-
ing between malignant and normal tissue is high, with a
Sensitivity of 90.5 % and Specificity of 90.1 %. This is
also reflected by the ROC curves, with an area under the
curve of 0.95. The ability of the sensor to differentiate
any abnormal tissue from normal tissue is also high,
Sensitivity 88.6 % and Specificity 91.7 %. With the
current false-negative rates of CNB, this level of sensitiv-
ity has the potential of reducing the false negative rates
in biopsy procedures to below 1 %.
The detection sensitivity of the sensor is dependent on
the feature size of the malignant tissue. A 90.2 % Sensi-
tivity features of at least 0.8 m in size, down to 66.8 %
sensitivity for features smaller than 0.5 mm. It is antici-
pated that most biopsied malignancies will be of at least
1 mm in size, as, based on final pathology, most all of
the malignant lesions are found to be larger than 3 mm.
There are some limitations to this type of sensor
design. The manufacturing process of the sensor has to
account for potential chemical modifications (over time)
of the senor face, which can affect the reflected signals.
Arranging sensors in a tightly packed array provides an
additional challenge in isolating the electrical response
of the individual sensors from their neighbors. The
tissue has to be in direct contact with the sensor. There-
fore, a practical device will need good attachment to
substrate, as any (air) voids between the sensor and the
tissue will skew the impedance measurement results.
The very low penetration depth may limit the scope of
applications in which this type of sensor will provide
benefit. The sensor is gold-plated, with gold known not
to be durable with regards to mechanical abrasion. In a
biopsy procedure each sensor would be used for a
limited duration, typically no more than a few minutes.
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Also, breast tissue is soft, and therefore it is not
expected that the sensor structure will be mechanically
effected during use.
Conclusion
By use of a miniature flexible radio-frequency near-field
spectroscopy sensor the dielectric properties of 10 tissue
types present within the breast were quantified, showing
distinct differences between the all these types. Using
these differences a good differentiating was achieved
between breast tissue states, specifically between cancer-
ous and normal tissue. The sensor’s dimensions and
design may enable the use of such sensors in minimally
invasive procedures, including breast biopsy.
Abbreviations
ADH: Atypical Ductal Hyperplasia; CNB: Core Needle Biopsy; DCIS: Ductal
Carcinoma In Situ; RF: Radio Frequency; ROC: Receiver Operating




The study was sponsored by Dune Medical devices.
Availability of data and materials
The data supporting the conclusions of this article is available upon request
to the corresponding author.
Authors’ contributions
ZK, HP, IH, PM, TK, IP, and TA participated in the design of the study. TZ, JS,
and JD performed the pathological evaluation. ZK and TE drafted the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study was performed at 3 sites under institutional review board approval
and in accordance with the Declaration of Helsinki. The IRBs that granted
study approval are: (1) Meir Hospital’s Helsinki committee (2) Assaf Harofeh
Medical Center’s Helsinki Committee and (3) Kaplan Medical Center’s Helsinki
Committee. All subjects signed an informed consent form.
Author details
1Breast unit, Meir Medical Center, Kfar Saba, Israel. 2Department of pathology,
Meir Medical Center, Kfar Saba, Israel. 3Breast unit, Assaf Harofeh Medical
Center, Zrifin, Israel. 4Department of Pathology, Assaf Harofeh Medical Center,
Zrifin, Israel. 5Department of Pathology, Kaplan Medical Center, Rehovot,
Israel. 6Breast Unit, Kaplan Medical Center, Rehovot, Israel. 7Department of
Surgery, Meir Medical Center, Kfar Sava, Israel.
Received: 3 August 2016 Accepted: 4 October 2016
References
1. Gabriel S, Lau RW, Gabriel C. The dielectric properties of biological tissue II:
Measurements in the frequency range 10 Hz to 20 GHz. Phys Med Biol.
1996;41:2251.
2. Foster KR, Schepps JL. Dielectric properties of tumor and normal tissues at
radio through microwave frequencies. J Micro Power. 1981;16(2):107–19.
3. Joines WT, Zhang Y, Li C, Jirtle RL. The measured electrical properties of
normal and malignant human tissues from 50 to 900 MHz. Med Phys.
1994;21(4):547–50.
4. Sha L, Ward ER, Stroy B. A review of dielectric properties of normal and
malignant breast tissue. PIEEE Southeast Con. 2002; 457-462.
5. Surowiec AJ, Stuchly SS, Barr JR, Swarup A. Dielectric properties of breast
carcinoma and the surrounding tissue. IEEE Trans Biomed Eng. 1988;35(4):257–63.
6. Zou Y, Guo Z. A review of electrical impedance techniques for breast
cancer. Med Eng Phys. 2003;25(2):79–90.
7. Lazebnik M, et al. A large-scale study of the ultrawideband microwave
dielectric properties of normal breast tissue obtained from reduction
surgeries. Phys Med Biol. 2007;52:6093–115.
8. Pappo I, Spector R, Schindel A, Morgenstern S, Sandbank J, Leider LT, et al.
Diagnostic performance of a novel device for real-time margin assessment
in lumpectomy specimens. J Surg Res. 2010;160(2):277–81.
9. Karni T, Pappo I, Sandbank J, Lavon O, Kent V, Spector R, et al. A device for
real-time, intraoperative margin assessment in breast-conservation surgery.
Am J Surg. 2007;194:467–73.
10. Allweis TM, Kaufman Z, Lelcuk S, Pappo I, Karni T, Schneebaum S, et al. A
prospective, randomized, controlled, multicenter study of a real-time,
intraoperative probe for positive margin detection in breast-conserving
surgery. Am J Surg. 2008;196:483.
11. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of
eliminating socioeconomic and racial disparities on premature cancer
deaths. CA Cancer J Clin. 2011;61:212.
12. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin.
2011;61:69.
13. Breast Imaging Reporting and Data System (BI-RADS) Atlas, 4th ed,
American College of Radiology, Reston, VA 2003.
14. Barlow WE, Lehman CD, Zheng Y, et al. Performance of diagnostic
mammography for women with signs or symptoms of breast cancer. J Natl
Cancer Inst. 2002;94:1.
15. Hubbard RA, Kerlikowske K, Flowers CI, et al. Cumulative probability of false
positive recall or biopsy recommendation after 10 years of screening
mammography: a cohort study. Ann Intern Med. 2011;155:481–92.
16. Ghosh K, Melton 3rd LJ, Suman VJ, Grant CS, Sterioff S, et al. Breastbiopsy
utilization: a population-based study. Arch Intern Med. 2005;165:1593–8.
17. Nelson HD, et al. Screening for breast cancer: an update for the U.S.
Preventive services task force. Ann Intern Med. 2009;151:727–37.
18. Chae BJ, Lee A, Song BJ, Jung SS. Predictive factors for breast cancer in
patients diagnosed atypical ductal hyperplasia at core needle biopsy. World
J Surg Oncol. 2009;7:77.
19. Elsheikh TM, Silverman JF. Follow-up surgical excision is indicated when
breast core needle biopsies show atypical lobular hyperplasia or lobular
carcinoma in situ: a correlative study of 33 patients with review of the
literature. Am J Surg Pathol. 2005;29:534.
20. Anderson BO, Calhoun KE, Rosen EL. Evolving concepts in the management
of lobular neoplasia. J Natl Compr Canc Netw. 2006;4:511.
21. Margenthaler JA, Duke D, Monsees BS, et al. Correlation between core biopsy
and excisional biopsy in breast high-risk lesions. Am J Surg. 2006;192:534.
22. Lui, et al. Rebiopsy after stereotactic core-needle breast biopsy: prospective
study. J HK Coll Radiol. 2004;7:116–20.
23. Youk JH, et al. Missed breast cancers at US-guided core needle biopsy: How
to reduce them, radio graphics, vol. 27. 2007. p. 79–94.
24. Brun del Re R. Minimally invasive breast biopsies, recent results in cancer
research 173. Berlin Heidelberg: Springer; 2009. p. 149.
25. Fajardo, et al. Stereotactic and sonographic large-core biopsy of
nonpalpable breast lesions: results of the radiologic diagnostic oncology
group V study. Acad Radiol. 2004;11(3):293–308.
26. Dotan ZA, Fridman E, Lindner A, Ramon J, Pode D, Bejar J, Kopolovic J, Pizov G,
Sandbank J, Katz R, Shapiro A, Shilo Y, Nativ O. Detection of prostate cancer by
radio-frequency near-field spectroscopy in radical prostatectomy ex vivo
specimens. Prostate Cancer Prostatic Dis. 2013;16(1):73–8.
27. Meaney PM, Williams BB, Geimer SD, Flood AB, Swartz HM. A coaxial
dielectric probe technique for distinguishing tooth enamel from dental
resin. Adv Biomed Eng Res. 2015;3:8–17.
28. Misra DK. A quasi-static analysis of open-ended coaxial lines. IEEE Trans
Microwave Theory Tech. 1987;MTT-35:925–8.
29. Dupont WD, Page DL. Risk factors for breast cancer in women with
proliferative breast disease. N Engl J Med. 1985;312:146–51. American
Cancer Society, Non-cancerous Breast Conditions.
Kaufman et al. BMC Medical Imaging  (2016) 16:57 Page 9 of 10
30. Rawlings JO, Pantula SG, Dickey DA. Applied regression analysis: a research
tool. Springer; 1998.
31. Estrela da Silva JE, Marques de Sa JP, Jossinet J. Classification of breast tissue by
electrical impedance spectroscopy. J Med Biol Eng Comput. 2000;38:26–30.
32. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J, editors. SEER
survival monograph: cancer survival among adults: U.S. SEER program,
1988-2001, patient and tumor characteristics. Bethesda: National Cancer
Institute; 2007. SEER Program, NIH Pub. No. 07-6215.
33. Gutwein LG, Ang DN, Liu H, et al. Utilization of minimally invasive breast
biopsy for the evaluation of suspicious breast lesions. Am J Surg. 2011;202:127.
34. Verkooijen HM, Core Biopsy After Radiological Localisation (COBRA) Study
Group. Diagnostic accuracy of stereotactic large-core needle biopsy for
nonpalpable breast disease: results of a multicenter prospective study with
95 % surgical confirmation. Int J Cancer. 2002;99:853.
35. Stomper PC, Winston PS, Proulx GM, et al. Mammographic detection and
staging of ductal carcinoma in situ: mammographic-pathologic correlation.
Semin Breast Dis. 2000;3:1.
36. Shah VI, Raju U, Chitale D, et al. False-negative core needle biopsies of the
breast: an analysis of clinical, radiologic, and pathologic findings in 27
consecutive cases of missed breast cancer. Cancer. 2003;97:1824.
37. Jackman RJ, Marzoni Jr FA, Rosenberg J. False-negative diagnoses at
stereotactic vacuum-assisted needle breast biopsy: long-term follow-up of
1,280 lesions and review of the literature. AJR Am J Roentgenol. 2009;192:341.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kaufman et al. BMC Medical Imaging  (2016) 16:57 Page 10 of 10
